Alruwaili M, Elderdery A, Ejaz H, Farhana A, Atif M, Almutary H
Trop Med Infect Dis. 2024; 9(11).
PMID: 39591290
PMC: 11597988.
DOI: 10.3390/tropicalmed9110284.
Santamaria A, Vasquez V, Rigg C, Moreno D, Romero L, Justo C
Life (Basel). 2020; 10(12).
PMID: 33260605
PMC: 7760695.
DOI: 10.3390/life10120319.
Toure O, Landry T, Assi S, Kone A, Gbessi E, Ako B
Infect Drug Resist. 2018; 11:2031-2038.
PMID: 30464545
PMC: 6208791.
DOI: 10.2147/IDR.S167518.
Messerli C, Hofmann N, Beck H, Felger I
Antimicrob Agents Chemother. 2016; 61(1).
PMID: 27821442
PMC: 5192142.
DOI: 10.1128/AAC.01500-16.
Laman M, Benjamin J, Moore B, Salib M, Tawat S, Davis W
Malar J. 2015; 14:121.
PMID: 25889150
PMC: 4374335.
DOI: 10.1186/s12936-015-0624-4.
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.
Laman M, Moore B, Benjamin J, Yadi G, Bona C, Warrel J
PLoS Med. 2014; 11(12):e1001773.
PMID: 25549086
PMC: 4280121.
DOI: 10.1371/journal.pmed.1001773.
Genetic diversity of Plasmodium falciparum among school-aged children from the Man region, western Côte d'Ivoire.
Mara S, Silue K, Raso G, Nguetta S, NGoran E, Tanner M
Malar J. 2013; 12:419.
PMID: 24228865
PMC: 3842749.
DOI: 10.1186/1475-2875-12-419.
Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.
Duparc S, Borghini-Fuhrer I, Craft C, Arbe-Barnes S, Miller R, Shin C
Malar J. 2013; 12:70.
PMID: 23433102
PMC: 3598551.
DOI: 10.1186/1475-2875-12-70.
Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial.
Kayentao K, Doumbo O, Penali L, Offianan A, Bhatt K, Kimani J
Malar J. 2012; 11:364.
PMID: 23113947
PMC: 3566922.
DOI: 10.1186/1475-2875-11-364.
Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.
Carrasquilla G, Baron C, Monsell E, Cousin M, Walter V, Lefevre G
Am J Trop Med Hyg. 2012; 86(1):75-83.
PMID: 22232454
PMC: 3247112.
DOI: 10.4269/ajtmh.2012.11-0192.
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast.
Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S
PLoS One. 2011; 6(11):e26005.
PMID: 22102856
PMC: 3213089.
DOI: 10.1371/journal.pone.0026005.
Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis.
Makanga M, Bassat Q, Falade C, Premji Z, Krudsood S, Hunt P
Am J Trop Med Hyg. 2011; 85(5):793-804.
PMID: 22049029
PMC: 3205621.
DOI: 10.4269/ajtmh.2011.11-0069.
Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology.
Ballif M, Hii J, Marfurt J, Crameri A, Fafale A, Felger I
Malar J. 2010; 9:270.
PMID: 20925934
PMC: 2959069.
DOI: 10.1186/1475-2875-9-270.
Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.
Marfurt J, Smith T, Hastings I, Muller I, Sie A, Oa O
Malar J. 2010; 9:8.
PMID: 20053293
PMC: 2820042.
DOI: 10.1186/1475-2875-9-8.
FlexiChip package: an universal microarray with a dedicated analysis software for high-thoughput SNPs detection linked to anti-malarial drug resistance.
Steenkeste N, Dillies M, Khim N, Sismeiro O, Chy S, Lim P
Malar J. 2009; 8:229.
PMID: 19828052
PMC: 2770542.
DOI: 10.1186/1475-2875-8-229.
Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2).
Liljander A, Wiklund L, Falk N, Kweku M, Martensson A, Felger I
Malar J. 2009; 8:78.
PMID: 19386138
PMC: 2680902.
DOI: 10.1186/1475-2875-8-78.
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
Stanisic D, Richards J, McCallum F, Michon P, King C, Schoepflin S
Infect Immun. 2009; 77(3):1165-74.
PMID: 19139189
PMC: 2643653.
DOI: 10.1128/IAI.01129-08.
Heterogeneous distribution of Plasmodium falciparum drug resistance haplotypes in subsets of the host population.
Schoepflin S, Marfurt J, Goroti M, Baisor M, Mueller I, Felger I
Malar J. 2008; 7:78.
PMID: 18460212
PMC: 2391149.
DOI: 10.1186/1475-2875-7-78.
The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea.
Marfurt J, Muller I, Sie A, Oa O, Reeder J, Smith T
Malar J. 2008; 7:61.
PMID: 18423045
PMC: 2377269.
DOI: 10.1186/1475-2875-7-61.
Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs.
Crameri A, Marfurt J, Mugittu K, Maire N, Regos A, Coppee J
J Clin Microbiol. 2007; 45(11):3685-91.
PMID: 17804664
PMC: 2168483.
DOI: 10.1128/JCM.01178-07.
